STOCK TITAN

[Form 4] Definitive Healthcare Corp. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Kevin Coop, who is listed as both Chief Executive Officer and a Director of Definitive Healthcare Corp. (DH), reported a transaction on 10/01/2025. The report shows a Code F(1) transaction disposing of 37,593 shares of Class A common stock at a price of $3.56 per share. The filing explains these shares were withheld by the issuer to satisfy the reporting person’s tax withholding obligations related to the vesting and settlement of previously reported restricted stock units. After the withholding, the reporting person beneficially owned 3,584,788 shares, held directly. The form is signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.

Kevin Coop, che è elencato come sia Chief Executive Officer sia Director di Definitive Healthcare Corp. (DH), ha segnalato una transazione il 10/01/2025. Il rapporto mostra una transazione codice F(1) che dispone di 37.593 azioni ordinarie di Classe A a un prezzo di 3,56 $ per azione. La documentazione spiega che queste azioni sono state trattenute dall'emittente per soddisfare gli obblighi di ritenuta fiscale della persona che riporta relativi al vesting e al regolamento di precedentemente riportate unità azionarie limitate. Dopo la trattenuta, la persona che riporta detieneva direttamente 3.584.788 azioni. Il modulo è firmato da un procuratore-in-fatto per conto della persona che riporta il 10/03/2025.

Kevin Coop, quien figura como tanto Director Ejecutivo (CEO) como Director de Definitive Healthcare Corp. (DH), reportó una transacción el 01/10/2025. El informe muestra una transacción código F(1) que dispone de 37.593 acciones de clase A de acción común a un precio de 3,56 $ por acción. La presentación explica que estas acciones fueron retenidas por el emisor para satisfacer las obligaciones de retención de impuestos de la persona reportante relacionadas con el vesting y el asentamiento de las unidades de acciones restringidas reportadas previamente. Después de la retención, la persona reportante poseía directamente 3.584.788 acciones. El formulario está firmado por un procurador en nombre de la persona reportante el 03/10/2025.

Kevin Coop은 Definitive Healthcare Corp. (DH)의 최고경영자(CEO)이자 이사로 모두 등재되어 있으며, 2025년 10월 1일 거래를 보고했습니다. 보고서는 F(1) 코드 거래로 Class A 일반주 37,593주를 주당 3.56 USD에 처분했음을 보여줍니다. 제출서는 이 주식이 vesting 및 이전에 보고된 제한주식단위의 정착/결제와 관련된 보고자의 세금 원천징수 의무를 충족시키기 위해 발행자가 보유했다고 설명합니다. 원천징수 후 보고자는 직접 보유한 3,584,788주를 유익하게 소유했습니다. 이 양식은 보고자를 대신해 대리인에 의해 2025년 10월 3일에 서명되었습니다.

Kevin Coop, qui est inscrit à la fois comme Chief Executive Officer et Director de Definitive Healthcare Corp. (DH), a déclaré une transaction le 10/01/2025. Le rapport indique une transaction de code F(1) consistant à se défaire de 37 593 actions ordinaires de classe A à un prix de 3,56 $ par action. Le dépôt explique que ces actions ont été retenues par l'émetteur pour satisfaire les obligations de retenue d'impôt de la personne déclarant liées à l'acquisition et au règlement des unités d'actions restreintes précédemment déclarées. Après la retenue, la personne déclarante détenait avantageusement 3 584 788 actions, directement détenues. Le formulaire est signé par un mandataire agissant au nom de la personne déclarant le 03/10/2025.

Kevin Coop, der sowohl als Chief Executive Officer als auch als Director von Definitive Healthcare Corp. (DH) aufgeführt ist, meldete eine Transaktion am 01.10.2025. Der Bericht zeigt eine Transaktion mit dem Code F(1), bei der 37.593 Class A Stammaktien zu einem Preis von 3,56 $ pro Aktie veräußert wurden. Die Einreichung erklärt, dass diese Aktien vom Emittenten einbehalten wurden, um die steuerlichen Abzugsverpflichtungen der meldenden Person im Zusammenhang mit dem Vesting und der Abwicklung der zuvor berichteten Restricted Stock Units zu erfüllen. Nach dem Einbehalt hielt die meldende Person direkt 3.584.788 Aktien. Das Formular ist am 03.10.2025 von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet worden.

Kevin Coop، المدرج كمدير تنفيذي ومدير في Definitive Healthcare Corp. (DH)، قد أبلغ عن صفقة في 10/01/2025. يظهر التقرير صفقة ذات الرمز F(1) تتصرف في 37,593 سهمًا من العادية من الفئة A بسعر 3.56 دولارًا للسهم الواحد. تشرح الوثيقة أن هذه الأسهم أُحتُجزت من قبل المصدر لتلبية التزامات حجز الضرائب الخاصة بالشخص المبلغ عنه والمتعلقة بالاستحقاق وتسوية وحدات الأسهم المقيدة التي أُبلغ عنها سابقًا. بعد الحجز، امتلك الشخص المبلغ عنه بشكل فاعل 3,584,788 سهمًا مباشرة. تم توقيع النموذج من قبل وكيل مفوَّض نيابةً عن الشخص المبلغ عنه في 10/03/2025.

Kevin Coop,他被列为 Definitive Healthcare Corp.(DH)的首席执行官(CEO)和董事,报告了2025年10月1日的交易。报告显示为 F(1) 代码的交易,处置 37,593 股 A 类普通股,价格为每股 3.56 美元。该申报文件解释称,这些股票被发行人扣留,以满足披露人因《归属与结算》先前披露的受限股票单位相关的税务代扣义务。扣留后,披露人直接持有 3,584,788 股。该表格由代表披露人的代理人在 2025年10月3日签署。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: CEO tax-withholding sale of 37,593 shares at $3.56, leaving 3,584,788 shares held.

This Form 4 documents a routine issuer-withheld transaction under Code F(1), where shares are surrendered to cover tax obligations from vesting restricted stock units. Such transactions do not indicate an open-market sale by the executive but reduce outstanding personal shareholdings by a specified amount.

Because the filing shows 3,584,788 shares remaining beneficially owned, the executive retains a substantial stake. The filing is informational for investors tracking insider ownership and compliance with Section 16 reporting requirements.

Kevin Coop, che è elencato come sia Chief Executive Officer sia Director di Definitive Healthcare Corp. (DH), ha segnalato una transazione il 10/01/2025. Il rapporto mostra una transazione codice F(1) che dispone di 37.593 azioni ordinarie di Classe A a un prezzo di 3,56 $ per azione. La documentazione spiega che queste azioni sono state trattenute dall'emittente per soddisfare gli obblighi di ritenuta fiscale della persona che riporta relativi al vesting e al regolamento di precedentemente riportate unità azionarie limitate. Dopo la trattenuta, la persona che riporta detieneva direttamente 3.584.788 azioni. Il modulo è firmato da un procuratore-in-fatto per conto della persona che riporta il 10/03/2025.

Kevin Coop, quien figura como tanto Director Ejecutivo (CEO) como Director de Definitive Healthcare Corp. (DH), reportó una transacción el 01/10/2025. El informe muestra una transacción código F(1) que dispone de 37.593 acciones de clase A de acción común a un precio de 3,56 $ por acción. La presentación explica que estas acciones fueron retenidas por el emisor para satisfacer las obligaciones de retención de impuestos de la persona reportante relacionadas con el vesting y el asentamiento de las unidades de acciones restringidas reportadas previamente. Después de la retención, la persona reportante poseía directamente 3.584.788 acciones. El formulario está firmado por un procurador en nombre de la persona reportante el 03/10/2025.

Kevin Coop은 Definitive Healthcare Corp. (DH)의 최고경영자(CEO)이자 이사로 모두 등재되어 있으며, 2025년 10월 1일 거래를 보고했습니다. 보고서는 F(1) 코드 거래로 Class A 일반주 37,593주를 주당 3.56 USD에 처분했음을 보여줍니다. 제출서는 이 주식이 vesting 및 이전에 보고된 제한주식단위의 정착/결제와 관련된 보고자의 세금 원천징수 의무를 충족시키기 위해 발행자가 보유했다고 설명합니다. 원천징수 후 보고자는 직접 보유한 3,584,788주를 유익하게 소유했습니다. 이 양식은 보고자를 대신해 대리인에 의해 2025년 10월 3일에 서명되었습니다.

Kevin Coop, qui est inscrit à la fois comme Chief Executive Officer et Director de Definitive Healthcare Corp. (DH), a déclaré une transaction le 10/01/2025. Le rapport indique une transaction de code F(1) consistant à se défaire de 37 593 actions ordinaires de classe A à un prix de 3,56 $ par action. Le dépôt explique que ces actions ont été retenues par l'émetteur pour satisfaire les obligations de retenue d'impôt de la personne déclarant liées à l'acquisition et au règlement des unités d'actions restreintes précédemment déclarées. Après la retenue, la personne déclarante détenait avantageusement 3 584 788 actions, directement détenues. Le formulaire est signé par un mandataire agissant au nom de la personne déclarant le 03/10/2025.

Kevin Coop, der sowohl als Chief Executive Officer als auch als Director von Definitive Healthcare Corp. (DH) aufgeführt ist, meldete eine Transaktion am 01.10.2025. Der Bericht zeigt eine Transaktion mit dem Code F(1), bei der 37.593 Class A Stammaktien zu einem Preis von 3,56 $ pro Aktie veräußert wurden. Die Einreichung erklärt, dass diese Aktien vom Emittenten einbehalten wurden, um die steuerlichen Abzugsverpflichtungen der meldenden Person im Zusammenhang mit dem Vesting und der Abwicklung der zuvor berichteten Restricted Stock Units zu erfüllen. Nach dem Einbehalt hielt die meldende Person direkt 3.584.788 Aktien. Das Formular ist am 03.10.2025 von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet worden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Coop Kevin

(Last) (First) (Middle)
C/O DEFINITIVE HEALTHCARE CORP.
492 OLD CONNECTICUT PATH, SUITE 401

(Street)
FRAMINGHAM MA 01701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Definitive Healthcare Corp. [ DH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/01/2025 F(1) 37,593 D $3.56 3,584,788 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Jonathan Paris, Attorney-in-Fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Definitive Healthcare Corp.

NASDAQ:DH

DH Rankings

DH Latest News

DH Latest SEC Filings

DH Stock Data

354.93M
29.71M
9.42%
95.91%
4%
Health Information Services
Services-prepackaged Software
Link
United States
FRAMINGHAM